Ocugen (OCGN) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products. Its primary goal is to provide patients with high therapeutic value medicines and contribute to improving their health outcomes. The company specializes in the treatment of ocular diseases, including rare eye disorders. Ocugen stock is suitable for investors interested in the biotechnology sector and those who want to support innovative treatment approaches. Add Ocugen stock to your watchlist on Bulios and gain access to the latest information about this company that is pushing the boundaries of ocular disease management.
Plus de 486 millions de cas de COVID-19 ont été signalés dans le monde, et si le COVID-19 devient une maladie endémique, il reste une opportunité majeure pour les développeurs de médicaments. Certains analystes prévoient que ces actions vont grimper de 246% à 355% l'année prochaine.
